Spots Global Cancer Trial Database for octreotide
Every month we try and update this database with for octreotide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion | NCT02920567 | Periampullary T... | Octreotide Placebo | 19 Years - 80 Years | Saint Vincent's Hospital, Korea | |
| Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors | NCT01755182 | Neuroendocrine ... | approved pharma... TAE | 18 Years - 80 Years | National Cancer Institute, Naples | |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | NCT05050942 | Gastro-enteropa... | CAM2029 Octreotide LAR Lanreotide ATG | 18 Years - | Camurus AB | |
| A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | NCT00781911 | Carcinoma Neuroendocrine ... | Cixutumumab depot octreotid... | 18 Years - | Eli Lilly and Company | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion | NCT02920567 | Periampullary T... | Octreotide Placebo | 19 Years - 80 Years | Saint Vincent's Hospital, Korea | |
| Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery | NCT03734627 | Esophageal Canc... Nutrition Disor... Appetite Disord... Dumping Syndrom... Delayed Gastric... Surgery | Octreotide Acet... Saline Solution Paracetamol Sulfasalazine Duodenal biopsy | 18 Years - | St. James's Hospital, Ireland | |
| The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery | NCT02381249 | Esophageal Neop... Stomach Neoplas... Weight Loss Malnutrition Pancreatic Neop... Duodenal Neopla... | Octreotide Placebo | 18 Years - 100 Years | St. James's Hospital, Ireland | |
| Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma | NCT00241020 | Advanced Hepato... | Octreotide | 18 Years - | Novartis | |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | NCT03289741 | Neuroendocrine ... | Octreotide LAR Lanreotide Questionnaires | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas | NCT02333565 | Recurrent Menin... Resistant Menin... | Everolimus Octreotide | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | NCT00171873 | Neuroendocrine ... | Octreotide LAR ... Placebo | 18 Years - | Philipps University Marburg Medical Center | |
| Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs | NCT03812939 | Gastric NET | Octreotide | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly | NCT00461149 | Acromegaly | Octreotide-LAR | 18 Years - | Federico II University | |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion | NCT02920567 | Periampullary T... | Octreotide Placebo | 19 Years - 80 Years | Saint Vincent's Hospital, Korea | |
| Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly | NCT00461149 | Acromegaly | Octreotide-LAR | 18 Years - | Federico II University | |
| Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer | NCT02385617 | Esophageal Neop... Stomach Neoplas... Weight Loss Malnutrition | Octreotide Placebo | 18 Years - 100 Years | St. James's Hospital, Ireland | |
| Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements. | NCT06085976 | Hepatic Carcino... Hepatic Metasta... | Octreotide Placebo | 18 Years - 80 Years | Clinica Universidad de Navarra, Universidad de Navarra | |
| Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs | NCT03812939 | Gastric NET | Octreotide | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | NCT00332969 | Thymoma | Octreotide | 18 Years - | Novartis | |
| GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma | NCT00495846 | Advanced Hepato... | Octreotide-LAR,... Locoregional tr... | 18 Years - 75 Years | Federico II University | |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | NCT05477576 | GEP-NET Gastroenteropan... Gastroenteropan... Neuroendocrine ... Carcinoid Carcinoid Tumor Pancreatic NET | RYZ101 Everolimus 10 m... Sunitinib 37.5 ... Octreotide LAR ... Lanreotide 120M... | 18 Years - | RayzeBio, Inc. | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | NCT00412061 | Carcinoid Tumor Malignant Carci... | Octreotide Placebo Everolimus | 18 Years - | Novartis | |
| Prediction of Tumor Shrinkage in Acromegaly | NCT00616408 | Acromegaly | Octreotide-LAR | 18 Years - 85 Years | Federico II University | |
| Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding | NCT02032784 | Adenoma | octreotide No Octreotide | 18 Years - 89 Years | AdventHealth | |
| Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea | NCT00582426 | Chemotherapy-in... | Octreotide Long... Standard Treatm... | 18 Years - 80 Years | Novartis | |
| Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy | NCT02457156 | Pancreatic Canc... | Blumgart Anasto... Cattell-Warren ... Octreotide | 18 Years - | University of Liverpool | |
| Palliative Management of Inoperable Malignant Bowel Obstruction | NCT04027348 | Malignant Bowel... | Dexamethasone Metoclopramide Octreotide | 18 Years - | Roswell Park Cancer Institute | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | NCT00005906 | Lymphangioleiom... Lymphangiomyoma... Pleural Effusio... Ascites | Octreotide | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs | NCT03812939 | Gastric NET | Octreotide | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| The Effect of Octreotide on Wound Drainage After Mastectomy | NCT05682209 | Seroma Followin... | Octreotide Inje... Sterile water | - | University College Hospital, Ibadan | |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | NCT02299089 | Acromegaly Neuroendocrine ... | octreotide Flui... | 18 Years - | Camurus AB | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | NCT00005906 | Lymphangioleiom... Lymphangiomyoma... Pleural Effusio... Ascites | Octreotide | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | NCT00332969 | Thymoma | Octreotide | 18 Years - | Novartis | |
| Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome | NCT00884715 | Carcinoid Syndr... | Octreotide | 18 Years - 80 Years | Endo Pharmaceuticals | |
| The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery | NCT02381249 | Esophageal Neop... Stomach Neoplas... Weight Loss Malnutrition Pancreatic Neop... Duodenal Neopla... | Octreotide Placebo | 18 Years - 100 Years | St. James's Hospital, Ireland | |
| Octreotide in Severe Polycystic Liver Disease | NCT00426153 | Polycystic Kidn... Polycystic Live... Hepatomegaly Liver Diseases Kidney, Polycys... Abdominal Pain | Octreotide Placebo | 18 Years - 80 Years | Mayo Clinic | |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | NCT00412061 | Carcinoid Tumor Malignant Carci... | Octreotide Placebo Everolimus | 18 Years - | Novartis | |
| Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs | NCT02294006 | Well Differenti... | Everolimus plus... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs | NCT02294006 | Well Differenti... | Everolimus plus... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | NCT02299089 | Acromegaly Neuroendocrine ... | octreotide Flui... | 18 Years - | Camurus AB |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
